Stock Market Reviews

IRD (Opus Genetics, Inc.) News

Get the latest news, insights, and market updates on IRD (Opus Genetics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside
  These biotech bets are only for investors who can stomach volatility.
  Dec 20, 2025 - $IRD
• Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  RESEARCH TRIANGLE PARK, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the Compensation Committee of its Board of Directors approved an equity award under the Company’s 2021 Inducement Plan, as amended, as a material inducement to employment to one non-e
  Dec 16, 2025 - $IRD
• Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference
  RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases, announced today that George Magrath, M.D., Chief Executive Officer, will present at the J.P. Morgan 2026 Healthcare Conference on Thursday, January 15, 2026 at 8:15 a.m. PT. A link to the live and archived webcas
  Dec 11, 2025 - $IRD
• Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease
  Initial favorable safety profile demonstrated in OPGx-BEST1 clinical trialRESEARCH TRIANGLE PARK, N.C., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the Independent Data Monitoring Committee (IDMC) issued a positive recommendation to continue as planned in the Comp
  Dec 9, 2025 - $IRD
• Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders (the “Company”), today announced that the Compensation Committee of its Board of Directors approved equity awards under the Company’s 2021 Inducement Plan, as amended, as a material inducement to employment to two non
  Dec 2, 2025 - $IRD
• Piper Sandler Initiates Coverage on Opus Genetics, Inc. (IRD) With “Overweight” Rating and $7 PT
  Opus Genetics, Inc. (NASDAQ:IRD) is one of the 12 hot penny stocks to invest in right now. On November 25, 2025, The Fly reported that Piper Sandler initiated coverage of Opus Genetics, Inc. (NASDAQ:IRD) with an “Overweight” rating and a $7 price target. The investment firm highlighted OPGx-LCA5, the company’s lead gene therapy program. The program aims […]
  Nov 29, 2025 - $IRD
• Opus Genetics to Participate in Upcoming Investment Conferences
  RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will participate in the following investor conferences. BTIG 5th Annual Ophthalmology Day (Virtual): Ash Jayagopal, PhD, MBA, Chief Scientific and Development Officer, will
  Nov 20, 2025 - $IRD
• Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease
  Emerging gene therapy administered through a one-time subretinal injection marks a major milestone for the inherited retinal disease community Initial data expected in Q1 2026 RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that the first par
  Nov 13, 2025 - $IRD
• Opus Genetics, Inc. (IRD) Reports Q3 Loss, Beats Revenue Estimates
  Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of +14.29% and +11.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 12, 2025 - $IRD
• Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update
  - Positive 3-month pediatric and 18-month adult clinical data from OPGx-LCA5 Phase 1/2 trial support the potential for restoring cone-mediated vision -- Successful FDA RMAT meeting provides the potential for an accelerated regulatory pathway to approval for OPGx-LCA5 -- OPGx-BEST1 gene therapy program underway with recruitment ongoing in Phase 1/2 trial for the treatment of BEST1 disease -- Supplemental New Drug Application submission planned by year-end 2025 for Phentolamine Ophthalmic Solution
  Nov 12, 2025 - $IRD